Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Y. Paul Goldberg is active.

Publication


Featured researches published by Y. Paul Goldberg.


Nature Genetics | 2004

Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis.

George Papanikolaou; Mark E. Samuels; Erwin H Ludwig; Marcia L.E. MacDonald; Patrick Franchini; Marie-Pierre Dubé; Lisa Andres; Julie MacFarlane; Nikos Sakellaropoulos; Marianna Politou; Elizabeta Nemeth; Jay Thompson; Jenni Risler; Catherine Zaborowska; Ryan Babakaiff; Christopher Charles Alexander Radomski; Terry D. Pape; Owen Davidas; John Christakis; Pierre Brissot; Gillian Lockitch; Tomas Ganz; Michael R. Hayden; Y. Paul Goldberg

Juvenile hemochromatosis is an early-onset autosomal recessive disorder of iron overload resulting in cardiomyopathy, diabetes and hypogonadism that presents in the teens and early 20s (refs. 1,2). Juvenile hemochromatosis has previously been linked to the centromeric region of chromosome 1q (refs. 3–6), a region that is incomplete in the human genome assembly. Here we report the positional cloning of the locus associated with juvenile hemochromatosis and the identification of a new gene crucial to iron metabolism. We finely mapped the recombinant interval in families of Greek descent and identified multiple deleterious mutations in a transcription unit of previously unknown function (LOC148738), now called HFE2, whose protein product we call hemojuvelin. Analysis of Greek, Canadian and French families indicated that one mutation, the amino acid substitution G320V, was observed in all three populations and accounted for two-thirds of the mutations found. HFE2 transcript expression was restricted to liver, heart and skeletal muscle, similar to that of hepcidin, a key protein implicated in iron metabolism. Urinary hepcidin levels were depressed in individuals with juvenile hemochromatosis, suggesting that hemojuvelin is probably not the hepcidin receptor. Rather, HFE2 seems to modulate hepcidin expression.


Nature Genetics | 2002

Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy

Johane Robitaille; Marcia L.E. MacDonald; Ajamete Kaykas; Laird C. Sheldahl; Jutta Zeisler; Marie-Pierre Dubé; Lin-Hua Zhang; Roshni R. Singaraja; Duane L. Guernsey; Binyou Zheng; Lee Siebert; Ann Hoskin-Mott; Michael T. Trese; Simon N. Pimstone; Barkur S. Shastry; Randall T. Moon; Michael R. Hayden; Y. Paul Goldberg; Mark E. Samuels

Familial exudative vitreoretinopathy (FEVR) is a hereditary ocular disorder characterized by a failure of peripheral retinal vascularization. Loci associated with FEVR map to 11q13–q23 (EVR1; OMIM 133780, ref. 1), Xp11.4 (EVR2; OMIM 305390, ref. 2) and 11p13–12 (EVR3; OMIM 605750, ref. 3). Here we have confirmed linkage to the 11q13–23 locus for autosomal dominant FEVR in one large multigenerational family and refined the disease locus to a genomic region spanning 1.55 Mb. Mutations in FZD4, encoding the putative Wnt receptor frizzled-4, segregated completely with affected individuals in the family and were detected in affected individuals from an additional unrelated family, but not in normal controls. FZD genes encode Wnt receptors, which are implicated in development and carcinogenesis. Injection of wildtype and mutated FZD4 into Xenopus laevis embryos revealed that wildtype, but not mutant, frizzled-4 activated calcium/calmodulin-dependent protein kinase II (CAMKII) and protein kinase C (PKC), components of the Wnt/Ca2+ signaling pathway. In one of the mutants, altered subcellular trafficking led to defective signaling. These findings support a function for frizzled-4 in retinal angiogenesis and establish the first association between a Wnt receptor and human disease.


Journal of Biological Chemistry | 1996

Huntingtin Is Ubiquitinated and Interacts with a Specific Ubiquitin-conjugating Enzyme

Michael Kalchman; Rona K. Graham; Gang Xia; H. Brook Koide; J.Graeme Hodgson; Kevin C. Graham; Y. Paul Goldberg; R. Dan Gietz; Cecile M. Pickart; Michael R. Hayden

Using the yeast two-hybrid system, we have identified a human ubiquitin-conjugating enzyme (hE2-25K) as a protein that interacts with the gene product for Huntington disease (HD) (Huntingtin). This protein has complete amino acid identity with the bovine E2-25K protein and has striking similarity to the UBC-1, −4 and −5 enzymes of Saccharomyces cerevisiae. This protein is highly expressed in brain and a slightly larger protein recognized by an anti-E2-25K polyclonal antibody is selectively expressed in brain regions affected in HD. The huntingtin-E2-25K interaction is not obviously modulated by CAG length. We also demonstrate that huntingtin is ubiquitinated. These findings have implications for the regulated catabolism of the gene product for HD.


Genomics | 1995

Genomic organization of the human α-adducin gene and its alternately spliced isoforms

Biaoyang Lin; Jamal Nasir; Helen McDonald; Rona K. Graham; Johanna M. Rommens; Y. Paul Goldberg; Michael R. Hayden

Abstract The cDNA for the human α-adducin gene has been cloned, and different alternately spliced forms have been identified. We report the complete genomic organization of the human α-adducin gene and these alternately spliced forms. The human α-adducin gene, spanning approximately 85 kb, consists of 16 exons ranging in size from 34 to 1892 bp. One of the spliced forms of the human α-adducin gene results from alternate use of the 5′ splice donor site for exon 10, while another results in a truncated protein following insertion of 34 bp comprising exon 15, followed by a premature stop codon. This alternate spliced form of α-adducin is predicted to result in an altered carboxyl terminus that would eliminate a protein kinase and calmodulin binding site. Seven nucleotide substitutions and 4 insertion/deletions were also identified. The 5′ region of the human α-adducin gene contains one Sp1 site, two AP2 sites, and two CAAT boxes. No TATA box was apparent, consistent with features of a housekeeping gene. We have mapped another cDNA within the first intron of the human α-adducin gene, suggesting overlapping genes in this 4p16.3 genomic region.


Clinical Genetics | 1999

Accurate determination of the number of CAG repeats in the Huntington disease gene using a sequence-specific internal DNA standard

Ove Bruland; Elisabeth W. Almqvist; Y. Paul Goldberg; Helge Boman; Michael R. Hayden; Per M. Knappskog

We have developed a sequence‐specific internal DNA size standard for the accurate determination of the number of CAG repeats in the Huntington disease (HD) gene by cloning key fragments (between 15 and 64 CAG repeats) of the HD gene. These fragments, pooled to produce a sequence‐specific DNA ladder, enabled us to observe the true number of CAG repeats directly, with no need for calculations. Comparison of the calculated numbers of CAG repeats in the HD gene using this sequence‐specific DNA standard with a commercially available standard (GENESCAN‐500 TAMRA) showed that the latter underestimated the number of CAG repeats by three when analyzed by capillary electrophoresis on the ABI 310 Genetic Analyzer (POP4 polymer). In contrast, the use of the same standard overestimated the number of CAG repeats by one when the samples were analyzed by denaturing polyacrylamide electrophoresis on ABI 377 DNA Sequencer (6% denaturing polyacrylamide gel). This suggests that our sequence‐specific standard provides greater accuracy for the determination of the true number of CAG repeats in the HD gene than commercially available standards. The sequence‐specific standard can be radioactively labeled and successfully replace conventional DNA size standards when analyzing polymerase chain reaction (PCR)‐amplified HD alleles by denaturing polyacrylamide electrophoresis.


Bioorganic & Medicinal Chemistry Letters | 2012

Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1)

Jay A. Cadieux; Zaihui Zhang; Maryanne Mattice; Alison Brownlie-Cutts; Jianmin Fu; Laszlo G. Ratkay; Rainbow Kwan; Jay Thompson; Joseph Sanghara; Jing Zhong; Y. Paul Goldberg

Three distinct series of substituted pyrazole blockers of divalent metal transporter 1 (DMT1) were elaborated from the high-throughput screening pyrazolone hit 1. Preliminary hit-to-lead efforts revealed a preference for electron-withdrawing substituents in the 4-amido-5-hydroxypyrazole series 6a-l. In turn, this preference was more pronounced in a series of 4-aryl-5-hydroxypyrazoles 8a-j. The representative analogs 6f and 12f were found to be efficacious in a rodent model of acute iron hyperabsorption. These three series represent promising starting points for lead optimization efforts aimed at the discovery of DMT1 blockers as iron overload therapeutics.


Journal of Medical Genetics | 2013

CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease

Alicia Semaka; Chris Kay; Crystal N. Doty; Jennifer A. Collins; Emilia K. Bijlsma; Fiona Richards; Y. Paul Goldberg; Michael R. Hayden

Introduction New mutations for Huntington disease (HD) occur due to CAG repeat instability of intermediate alleles (IA). IAs have between 27 and 35 CAG repeats, a range just below the disease threshold of 36 repeats. While they usually do not confer the HD phenotype, IAs are prone to paternal germline CAG repeat instability. Consequently, they may expand into the HD range upon transmission to the next generation, producing a new mutation. Quantified risk estimates for IA repeat instability are extremely limited but needed to inform clinical practice. Methods Using small-pool PCR of sperm DNA from Caucasian men, we examined the frequency and magnitude of CAG repeat instability across the entire range of intermediate CAG sizes. The CAG size-specific risk estimates generated are based on the largest sample size ever examined, including 30 IAs and 18 198 sperm. Results Our findings demonstrate a significant risk of new mutations. While all intermediate CAG sizes demonstrated repeat expansion into the HD range, alleles with 34 and 35 CAG repeats were associated with the highest risk of a new mutation (2.4% and 21.0%, respectively). IAs with ≥33 CAG repeats showed a dramatic increase in the frequency of instability and a switch towards a preponderance of repeat expansions over contractions. Conclusions These data provide novel insights into the origins of new mutations for HD. The CAG size-specific risk estimates inform clinical practice and provide accurate risk information for persons who receive an IA predictive test result.


Bioorganic & Medicinal Chemistry Letters | 2012

Discovery of benzylisothioureas as potent divalent metal transporter 1 (DMT1) inhibitors

Zaihui Zhang; Vishnumurthy Kodumuru; Serguei Sviridov; Shifeng Liu; Mikhail Chafeev; Sultan Chowdhury; Nagasree Chakka; Jianyu Sun; Simon James Gauthier; Maryanne Mattice; Laszlo G. Ratkay; Rainbow Kwan; Jay Thompson; Alison Cutts; Jianmin Fu; Rajender Kamboj; Y. Paul Goldberg; Jay A. Cadieux

Inhibition of intestinal brush border DMT1 offers a novel therapeutic approach to the prevention and treatment of disorders of iron overload. Several series of diaryl and tricyclic benzylisothiourea compounds as novel and potent DMT1 inhibitors were discovered from the original hit compound 1. These compounds demonstrated in vitro potency against DMT1, desirable cell permeability properties and a dose-dependent inhibition of iron uptake in an acute rat model of iron hyperabsorption. Tricyclic compounds increased the in vitro potency by up to 16-fold versus the original hit. Diaryl compounds 6b and 14a demonstrated significant iron absorption inhibition in vivo with both 25 and 50 mg/kg doses. The diaryl and tricyclic compounds described in this report represent promising structural templates for further optimization.


Nature Genetics | 1993

The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

Susan E. Andrew; Y. Paul Goldberg; Berry Kremer; Telenius H; Jane Theilmann; Shelin Adam; Elizabeth Starr; Ferdinando Squitieri; Biaoyang Lin; Michael Kalchman; Rona K. Graham; Michael R. Hayden


Blood | 2005

Hepcidin in iron overload disorders

George Papanikolaou; Michalis Tzilianos; John Christakis; Dionisios Bogdanos; Konstantina Tsimirika; Julie MacFarlane; Y. Paul Goldberg; Nikos Sakellaropoulos; Tomas Ganz; Elizabeta Nemeth

Collaboration


Dive into the Y. Paul Goldberg's collaboration.

Top Co-Authors

Avatar

Michael R. Hayden

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Rona K. Graham

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Jamal Nasir

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Michael Kalchman

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Biaoyang Lin

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Helen McDonald

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marcia L.E. MacDonald

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge